Pharmaceuticals, Biotechnology and Life Sciences
Eli Lilly has bought a biotech company focusing on pain management, CoLucid Pharmaceuticals for approximately $960 million, ($46.50 per share)…
AstraZeneca has sold to Pfizer the commercialization and development rights of its late-stage small molecule antibiotics business, comprising the approved antibiotics Merrem, Zinforo and Zavicefta, and ATM-AVI and CXL, which are in clinical development.
Xbrane Biopharma has named Anders P. Wiklund as strategic advisor. He presently serves on the boards of EffRx Pharmaceuticals SA, Inspirion Delivery Technologies LLC, Life Medical AB and IRRAS AB.
Pfizer is moving forward with Ibrance breast cancer drug as the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA).
Pfizer and Astellas Pharma have announced the Phase 4 PLATO study, evaluating the efficacy and safety of continued treatment with…
U.S. Food and Drug Administration (FDA) has approved Pfizer’s Eucrisa (crisaborole) ointment 2%, a novel non-steroidal topical phosphodieterase-4 (PDE-4) inhibitor…
Pfizer announced today the discontinuation of the global clinical development program for bococizumab…
Astellas Pharma and Pfizer have announced the FDA approved a supplemental New …
Pfizer will begin shipment of INFLECTRA (infliximab-dyyb) for injection, a biosimilar of REMICADE 1 (infliximab) to wholesalers in the United States (U.S.) in late November 2016.
Pfizer said on Thursday it would sell its global infusion therapy business, part of its $15 billion (11.8 billion pounds) Hospira acquisition last year, to ICU Medical Inc for $1 billion in cash and stock.